Drug Profile
Amelubant
Alternative Names: BIIL 284Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Amidines; Anti-inflammatories; Antiasthmatics; Antirheumatics; Carbamates
- Mechanism of Action Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis; Rheumatoid arthritis
Most Recent Events
- 28 Oct 2004 Discontinued - Phase-II for Rheumatoid arthritis in USA (unspecified route)
- 28 Oct 2004 Data presented at the 68th Annual Scientific Meeting of the American College of Rheumatology and the 39th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2004) have been added to the adverse events and Rheumatic disease therapeutic trials sections
- 26 Jun 2002 Amelubant has received orphan drug status for cystic fibrosis in the European Union